Suppr超能文献

2005年个人向日本进口药品情况——进口证书分析

Personal imports of drugs to Japan in 2005--an analysis of import certificates.

作者信息

Tsuji K, Tsutani K

机构信息

The Health Care Science Institute, Tokyo, Japan.

出版信息

J Clin Pharm Ther. 2008 Oct;33(5):545-52. doi: 10.1111/j.1365-2710.2008.00941.x.

Abstract

BACKGROUND

Personal imports of unapproved drugs are made by physicians and patients in Japan. Such imports require submission of a request for an import certificate from the Regional Bureau of Health and Welfare (RBHW). So far, there have been few reports on personal imports of drugs in Japan.

OBJECTIVE

To assess the extent and nature of personal imports of drugs in Japan.

METHODS

The date, product name and amount of drug imported were provided by RBHW for each personal import made by physicians in 2005. All imports were classified into several groups including whether they were for 'prescription drugs for non-cosmetic use (PDNC)' or 'prescription drugs for cosmetic use (PDC)'. Identification of PDNC was made by International Non-proprietary Name (INN). All drugs were classified under therapeutic groups. For the most frequently imported unapproved drugs, the approval year in the US/EU and development status in Japan were recorded.

RESULTS

A total of 12 196 personal imports were initiated by physicians in 2005. 5428 were for PDNCs corresponding to 242 drugs by INN. 55 PDNCs were each the subject of 10 or more imports. 11 drugs (252 imports) out of the top 55 PDNCs were available on the Japanese market during 2005 and 44 (4713 imports) were not approved. Of the 44 unapproved drugs, 11 (1019 imports) had been approved and 10 (2785 imports) were in the pre-registration phase as of December 31, 2006. Of the 44 unapproved drugs, 12 (1213 imports) were approved during 2000-2004, and 17 (3138 imports), during 1995-1999 in the US or EU. While the majority of imported drugs were antineoplastic drugs, drugs for various kinds of non-serious diseases were also imported.

CONCLUSIONS

A substantial number of unapproved drugs were being imported to Japan. A formal system for monitoring the use of those drugs should be established.

摘要

背景

在日本,医生和患者会个人进口未经批准的药物。此类进口需要向地区卫生和福利局(RBHW)提交进口证书申请。到目前为止,日本关于个人进口药物的报道很少。

目的

评估日本个人进口药物的程度和性质。

方法

RBHW提供了2005年医生每次个人进口药物的日期、产品名称和数量。所有进口药物被分为几个类别,包括是否为“非美容用途处方药(PDNC)”或“美容用途处方药(PDC)”。通过国际非专利名称(INN)识别PDNC。所有药物按照治疗类别进行分类。对于最常进口的未经批准的药物,记录其在美国/欧盟的批准年份和在日本的研发状态。

结果

2005年医生发起了总共12196次个人进口。5428次是用于PDNC的,对应242种通过INN识别的药物。55种PDNC每种都有10次或更多次进口。在最常进口的55种PDNC中,有11种药物(252次进口)在2005年可在日本市场获得,44种(4713次进口)未获批准。在这44种未获批准的药物中,截至2006年12月31日,有11种(1019次进口)已获批准,10种(2785次进口)处于预注册阶段。在这44种未获批准的药物中,有12种(1213次进口)在2000 - 2004年期间获得批准,17种(3138次进口)在1995 - 1999年期间在美国或欧盟获得批准。虽然大多数进口药物是抗肿瘤药物,但也进口了用于各种非严重疾病的药物。

结论

大量未经批准的药物被进口到日本。应建立一个正式的系统来监测这些药物的使用情况。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验